## Please type a plus sign (+) inside this box --> +

UTILITY	Attorney Do	cket No.	PC19084/AG0116-US							
PATENT APPLICATION	First Invento	or	David Matthews							
TRANSMITTAL	Title		PIN1 PEPTIDYL-PROLYL ISOMERASE POLYPEPTIDES, THEIF CRYSTAL STRUCTURES, AND USE THEREOF FOR DRUG DESIGN							
(Only for new nonapplications under 37C.F.R. §1.53(b))	Express Ma	il Label No.	EV 341079666	US						
APPLICATION ELEMEN See MPEP chapter 600 concerning utility patent ap		ADI	Mail Stop <u>Patent Applications</u> ADDRESS TO: Commissioner for Patents Box 1450 Alexandria, VA 22313-1450							
*Fee Transmittal Form (e.g., PTI (Submit an original, and a duplicate for fee)     Applicant claims small entity state	processing) US	(if a	computer Program (Appendix)							
(preferred arrangement set forth It - Descriptive title of the Invention - Cross References to Related - Statement Regarding Fed spotential of the Invention of	pelow) on Applications onsored R&D , a table,		b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies) ii. Paper c. Statement verifying identity of above copies							
- Background of the Invention			ACCOMPAN'	YING APPL	ICATION PARTS					
<ul> <li>Brief Summary of the Inventio</li> <li>Brief Description of the Drawii</li> <li>Detailed Description</li> <li>Claim(s)</li> <li>Abstract of the Disclosure</li> </ul>		9.	37 CFR 3.73(b) (when there is	Statement s an assignee	sheet & document(s))  Power of Attorney  ent (if applicable)					
4. Drawing(s) (35 U.S.C. 113) [Total	sheets	] 12.	Information Di Statement (ID	sclosure	Copies of IDS					
5. Cath or Declaration [Tota	pages 4	<sup>J</sup> 13	Preliminary Ar	mendment						
a. Newly executed (original		14.	Return Receip		· ·					
b. Copy from a prior application  (for continuation/divisional w.  i. DELETION OF		15.	Certified Copy (if foreign prio	of Priority D	ocument(s)					
Signed statement attached named in the prior applicat 1.63(d)(2) and 1.33(b).	deleting inventor(s)	16.	Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.							
6 Application Data Sheet. See 37 (	CFR 1.76	17.	Other:							
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.										
Continuation Divisional	Continuat	ion-in-part (CII	-in-part (CIP) of prior application No:/							
Prior application information: Examiner Group/Art Unit:										
For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts										
18. CORRESPONDENCE ADDRESS										
Customer Number or Bar Code Label  (Insert Customer No. or Attach bar code label here) or Correspondence address below  28940										
Name Agouron Pharmaceuticals, Inc.	Agouron Pharmaceuticals, Inc.									
Address 10777 Science Center Drive	10777 Science Center Drive									
City San Diego	State	CA		92121						
Country USA	Telephone	858/62	2-8060	Fax	858/678-8233					
NAME (Print/type) Karl Neidert	Ma 1 A	Registration	n No. (Attorney/	(Agent)	39,313					



PTO/SB/17(01/03)
Approved for use through 04/30/2003, OMB 0851-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number.

FEE TRANSMITTAL							Complete if Known								
						Ap	Application Number							ل	
							Fil	ling Da	ate						
for FY 2003						Fit	rst Na	med Inve	entor		David Matth ws				
							Ex	kamine	er Name			U			4
	licant o	laims sr	mall sta	itus. See 3	37 CFR 1.2	27	Ar	Art Unit							Ŧ
Total A				<u>-</u>	,910.00		At	Attorney Docket No. PC19084/AG0116-US						3	
-	M	ETHOD (	OF PAY	MENT (che	ck all that a	(vlan					FEE CAL	CULATION (continued)			5
Che						Other None	3. /	ADDIT	IONAL FE	ES '					Ť
☑ Deposit Account:							Large I	Entity	Small	Entity					
Deposit Account 500329							Fee ode	Fee	Fee Code	Fee (\$)	Fee Descri	ption	Fee		
Number 500329						"	oue	(\$)	Oout	(Ψ)			Paid		
Deposit						10	051	130	2051	65	Surcharge - late fee or	r oath		١	
Account Name Agouron Pharmaceuticals, Inc.													١		
			_				10	052	50	2052	25	Surcharge-late filing fe	e or cover		١
The Commissioner is authorized to: (check all that apply)										,	sheet		$\equiv$	١	
Charge fee(s) indicated below Credit any overpayments						053 812	130 2,520	1053 1812	130 2,520	Non-English specificati For filing a request for					
Charge any additional fee(s) during the pendency of this application				- 1		<i>'</i>			•			-			
Charge fee(s) indicated below, except for the filling fee to the above- identified deposit account.				"   1	804	920*	1804	920*	Requesting publication Examiner action	i oi SiH prior to		1			
						11	805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action				
			FEE C	CALCULATI	ION		1:	251	110	2251	55	Extension for reply with	nin first month		
1. BASIC FILING FEE					1:	252	410	2252	205	Extension for reply within second month					
Large E	ntity	Small	Entity				1:	253	930	2253	465	Extension for reply with	hin third month		
<u>Fee</u> Code	<u>Fee</u> (\$)	<u>Fee</u> Code	<u>Fee</u> (\$)	Fee Des	scription	Fee Paid	12	254	1,450	2254	725	Extension for reply with month	hin fourth		
1001	750	2001	375	Utility filing	g fee	750	1:	255	1,970	2255	985	Extension for reply with	hin fifth month		
1002	330	2002	165	Design filir	na fee		14	401	320	2401	160	Notice of Appeal			
1003	520	2003	260	Plant filing				402	320	2402	160	Filing a brief in support		4-4	
1004	750	2004	375	Reissue fil	lina fee			403 451	280 1,510	2403 1451	140 1,510	Request for oral hearing Petition to institute a pro-			- 1
1005	160	2005	80	filing fee			-   '	401	1,510	1451	1,510	proceeding	ablic ase		
SUBTOTAL (1) 750						1.	452	110	2452	55	Petition to revive - una				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE					1.	453	1,300	2453	650	Petition to revive - unintentional					
Extra Fee from Claims below Fee Paid					1:	501	1,300	2501	650	Utility issue fee (or reissue)					
Total Clair	ns	56 -	20**=	36	X 18	= 648	1	502	470	2502	235	Design issue fee			ĺ
Independe	ent	21 .	3**=	18	χ 84	<sub>=</sub> 1512	1	503	630	2503	315	Plant issue fee			
Claims  Multiple Dependent = 0				1.	460	130	1460	130	Petitions to the Commissioner						
Multiple Dependent = 0  ** or number previously paid, if greater; For Reissues, see below					807	50	1807	50	Processing fee under 37 CFR 1.17 (q)						
Large Entity Small Entity				11	801	750	2801	375	Request for Continued Examination						
Fee	Fee	Fee	Fee	- Fee Desc	cription			806	180	1806	180	(RCE) Submission of Informa	tion Disclosure		
Code	(\$)	Code	(\$)	100 000	<del>Miption</del>		'	000	100	1000	100	Statement	non Disclosure		
1202	18	2202	9	Claims in e	excess of 2	0	8	021	40	8021	40	Recording each patent per property (times nul			
1201	84	2201	42	Independe	ent claims in	excess of 3	1	809	750	2809	375	properties) Filing a submission after final rejection [ (37 CFR 1.129(a))			
1203	280	2203	140	Multiple de	apendent cl	aim, if not paid	1	810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))			
1204	84	2204	42	**Reissue original p		nt claims over	Ot	Other Fee (specify)							
1205	18	2205	9		claims in e ginal patent	xcess of 20 and	*R	*Reduced by Basic Filing Fee Paid							
SUBTOTAL (2) (\$) 2160												SUBTOTAL	(3) (\$)		
SUBMITTED BY								Complete (if Applicable)							П
Name (Printed/Type) Karl Neidert					7.	Reg. Number 39,313						7			
Signature Hand Merch					D	Date         July 2003         Telephone         858/622-8060						!			
		•	,	7											

PC19084-AG0116-US
Patent Application Transmittal

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV 341079666US in an envelope addressed to: Mail Stop Patent Applications, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 8th day of July 2003.

Group Art Unit: Not yet assigned

**Examiner: Not yet assigned** 

s/ Well Masself
Karl Neidert

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: David Matthews et al.

Serial No.: Not yet assigned

Filed: Herewith

For: PIN1 PEPTIDYL-PROLYL ISOMERASE

POLYPEPTIDES, THEIR CRYSTAL STRUCTURES, AND USE THEREOF FOR

**DRUG DESIGN** 

Mail Stop: Patent Applications Commissioner For Patents P.O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Utility Patent Application Transmittal 71 pages
- 2. Fee Transmittal (in duplicate)
- 3. Application Data Sheet (4 pages)
- 4. Specification (Total 71 pages)
  - Claims
  - Abstract
- 5. Return Postcard

Total Fee Due \$2,910.00 - Deposit Account

Respectfully submitted,

Date: July 8, 2003

Karl Neidert
Attorney For Applicants
Registration No. 39,313

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-8060

Fax: (858) 678-8233